108521-99-9

Basic information

• Product Name: (R)-3-Acetoxymethyl-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid allyl ester
• Synonyms: (R)-3-Acetoxymethyl-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid allyl ester
• CAS NO: 108521-99-9
• Molecular Weight: 430.481
• Mol File: 108521-99-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-3-Acetoxymethyl-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid allyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-Acetoxymethyl-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid allyl ester(108521-99-9)
• EPA Substance Registry System: (R)-3-Acetoxymethyl-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid allyl ester(108521-99-9)

Safety Data

• Hazardous Substances Data: 108521-99-9(Hazardous Substances Data)

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 106-95-6 allyl bromide 
• 957-68-6 7-Aminocephalosporanic acid 

Downstream Products

• 949145-03-3 allylI doxaz-cephem 
• 949145-02-2 C₂₆H₂₃N₃O₉S 
• 140647-39-8 ((6R,7R)-2-Allyloxycarbonyl-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-en-3-ylmethyl)-triphenyl-phosphonium; iodide 
• 140647-40-1 (6R,7R)-8-Oxo-7-phenylacetylamino-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid allyl ester 
• 859-07-4 (R)-3-Acetoxymethyl-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 140647-36-5 (6R,7R)-3-Iodomethyl-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid allyl ester 

Relevant articles and documents

METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF

The invention provides therapeutically effective compounds for the prevention and treatment of cancer and pharmaceutical compositions containing these compounds as well as methods of using and administering these compounds. The invention also includes methods of activating a prodrug of these therapeutically effective compounds by the administration of a peptide-directed targeting construct that delivers a prodrug-activating enzyme to a target activation site.